New role uncovered for ‘oldest’ tumour suppressor gene- the retinoblastoma gene
26 March 2015 | By Victoria White
Scientists have revealed a brand new function for one of the first cancer genes ever discovered – the retinoblastoma gene...
List view / Grid view
News
Taconic Biosciences and Cellaria Biosciences agree to scientific collaboration to facilitate xenograft use in oncology research
26 March 2015 | By Victoria White
Taconic and Cellaria have entered into a scientific collaboration to facilitate use of patient-derived xenografts in animal models for oncology research...
Medical breakthroughs on the horizon with £32m boost from the Biomedical Catalyst
26 March 2015 | By Victoria White
New treatments, diagnostics and medical technologies are set to benefit from an investment of £32 million through the Biomedical Catalyst...
AstraZeneca to collaborate with the HSCI in search for new diabetes treatments
25 March 2015 | By Victoria White
AstraZeneca to collaborate with the HSCI to adapt a technique that creates human beta cells from stem cells to search for new treatments for diabetes...
Cancer Research UK partners with the Engineering and Physical Sciences Research Council (EPSRC) to inspire innovation
25 March 2015 | By Victoria White
Cancer Research UK has partnered with the EPSRC to co-fund multidisciplinary research projects with up to £37.5m in funding available over five years...
Semma Therapeutics announces $44 million in funding to develop cell therapy for treating Type 1 diabetes
24 March 2015 | By Victoria White
Semma, a company developing cell therapy for T1D, announces that it has closed a $44 million Series A consisting of equity financing and strategic funding...
Bristol-Myers Squibb acquires exclusive license from Novo Nordisk for a discovery research programme focused on autoimmune diseases
24 March 2015 | By Victoria White
Bristol-Myers Squibb acquires license from Novo Nordisk for a discovery biologics research programme focused on modulating the innate immune system...
Rigontec GmbH raises €4.8m in a second closing of its Series A financing
24 March 2015 | By Victoria White
Rigontec, a company developing RNA-based immunotherapeutics, today announces it has raised €4.8 million in a second closing of its Series A financing round...
Detecting prostate tumour cells in blood can give an early warning of treatment failure
23 March 2015 | By Victoria White
A blood test that measures the number of prostate tumour cells shed into the bloodstream can act as an early warning sign that treatment is not working...
Confluence Pharmaceuticals signs co-development and marketing agreement with AOP Orphan for Fragile X Syndrome drug
23 March 2015 | By Victoria White
Confluence and AOP have signed an agreement to co-develop and market a product for the treatment of Fragile X Syndrome in Europe and the Middle East...
A vaccine against placental malaria made with ExpreS2ion Biotechnologies’ protein expression technology, ExpreS2, is ready to start human tests in Germany and Benin
20 March 2015 | By Victoria White
ExpreS2ion Biotechnologies announce the release by its partners at University of Copenhagen of a vaccine against placental malaria for testing in humans...
Probiodrug to present data on its Anti-pGlu-3 Abeta monoclonal Antibody at the 12th International Conference on Alzheimer’s and Parkinson’s Diseases
20 March 2015 | By Victoria White
Probiodrug has announced that the company will present data on its specific pGlu-Abeta mouse antibody 17/1 at AD/PDTM 2015 in Nice, France...
Prothena reports robust reduction of free serum alpha-synuclein of up to 96% after single dose of PRX002, a novel protein immunotherapy for Parkinson’s disease
20 March 2015 | By Victoria White
Prothena has announced positive results from a study of PRX002, a monoclonal antibody for the potential treatment of Parkinson's disease...
Alizé Pharma III raises €1.8 million ($1.94 million) in first financing round
19 March 2015 | By Victoria White
Alizé Pharma III SAS, a company specialised in the development of biopharmaceutical products, has raised €1.8 million in a first financing round...
Targeted therapies offer novel treatment modalities for breast cancer
19 March 2015 | By Victoria White
While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted therapies is on the rise...
